Woodcock Eric A, Lundahl Leslie H, Greenwald Mark K
Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, MI 48201, USA; Translational Neuroscience Program, Wayne State University, Detroit, MI 48201, USA.
Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, MI 48201, USA.
Drug Alcohol Depend. 2015 Jan 1;146:89-96. doi: 10.1016/j.drugalcdep.2014.11.016. Epub 2014 Nov 26.
Buprenorphine (BUP) is effective for treating opioid use disorder. Individuals' heroin-use characteristics may predict their responses to BUP, which could differ during maintenance and dose-taper phases. If so, treatment providers could use pre-treatment characteristics to personalize level of individual care and possibly improve treatment outcomes.
Non-treatment-seeking heroin-dependent volunteers (N=34) initiated outpatient BUP maintenance (8-mg/day) and submitted urine samples thrice weekly tested for opioids (non-contingent result). After completing three programmatically-related inpatient behavioral pharmacology experiments (while maintained on 8-mg/day BUP), participants were discharged and underwent a double-blind BUP dose taper (4-mg/day, 2-mg/day and 0-mg/day during weeks 1-3, respectively) with an opioid-abstinence incentive ($30 per consecutive opioid-negative urine specimen, obtained thrice weekly).
Participants who reported less pre-study (past-month) heroin use and shorter lifetime duration of heroin use were more likely to submit an opioid-negative urine sample during initial outpatient BUP maintenance. Participants who reported more lifetime heroin-quit attempts and provided any opioid-free urine sample during initial outpatient maintenance sustained longer continuous opioid-abstinence during the BUP dose taper. Participants who reported >3 lifetime quit attempts abstained from opioid use nearly one week longer (14 days vs. 8 days to opioid-lapse) and nearly half (46.7%) refrained from opioid use during dose taper.
Number of prior heroin quit attempts may predict BUP dose taper response and provide a metric for stratifying heroin-dependent individuals by relative risk for opioid lapse. This metric may inform personalized relapse prevention care and improve treatment outcomes.
丁丙诺啡(BUP)对治疗阿片类药物使用障碍有效。个体的海洛因使用特征可能预测其对丁丙诺啡的反应,这种反应在维持阶段和剂量递减阶段可能有所不同。如果是这样,治疗提供者可以利用治疗前的特征来个性化个体护理水平,并可能改善治疗结果。
未寻求治疗的海洛因依赖志愿者(N = 34)开始门诊丁丙诺啡维持治疗(8毫克/天),并每周三次提交尿液样本检测阿片类药物(非偶然结果)。在完成三项与项目相关的住院行为药理学实验(同时维持8毫克/天的丁丙诺啡治疗)后,参与者出院并接受双盲丁丙诺啡剂量递减(第1 - 3周分别为4毫克/天、2毫克/天和0毫克/天),并有阿片类药物戒断激励(每连续一份阿片类药物阴性尿液样本奖励30美元,每周三次采集)。
报告研究前(过去一个月)海洛因使用较少且海洛因使用终生持续时间较短的参与者在初始门诊丁丙诺啡维持治疗期间更有可能提交阿片类药物阴性尿液样本。报告更多终生海洛因戒断尝试且在初始门诊维持治疗期间提供过任何无阿片类药物尿液样本的参与者在丁丙诺啡剂量递减期间维持持续阿片类药物戒断的时间更长。报告终生戒断尝试次数>3次的参与者阿片类药物使用戒断时间延长近一周(阿片类药物复吸时间为14天 vs. 8天),并且近一半(46.7%)在剂量递减期间未使用阿片类药物。
既往海洛因戒断尝试次数可能预测丁丙诺啡剂量递减反应,并为根据阿片类药物复吸的相对风险对海洛因依赖个体进行分层提供一个指标。该指标可为个性化的预防复吸护理提供参考并改善治疗结果。